Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioceres Crop Solutions (BIOX) Equity Average (2017 - 2026)

Bioceres Crop Solutions' Equity Average history spans 9 years, with the latest figure at $166.5 million for Q1 2026.

  • On a quarterly basis, Equity Average changed N/A to $166.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $166.5 million, a N/A change, with the full-year FY2025 number at $308.4 million, down 9.55% from a year prior.
  • Equity Average hit $166.5 million in Q1 2026 for Bioceres Crop Solutions, down from $340.9 million in the prior quarter.
  • Over the last five years, Equity Average for BIOX hit a ceiling of $340.9 million in Q2 2024 and a floor of $166.5 million in Q1 2026.
  • Historically, Equity Average has averaged $256.1 million across 4 years, with a median of $258.5 million in 2022.
  • Biggest five-year swings in Equity Average: skyrocketed 462.75% in 2022 and later decreased 10.37% in 2023.
  • Tracing BIOX's Equity Average over 4 years: stood at $272.7 million in 2022, then dropped by 10.37% to $244.4 million in 2023, then skyrocketed by 39.5% to $340.9 million in 2024, then crashed by 51.15% to $166.5 million in 2026.
  • Business Quant data shows Equity Average for BIOX at $166.5 million in Q1 2026, $340.9 million in Q2 2024, and $244.4 million in Q2 2023.